Telisotuzumab Vedotin Plus Erlotinib in c-Met Protein–Expressing NSCLC
In a phase Ib trial reported in the Journal of Clinical Oncology, D. Ross Camidge, MD, PhD, and colleagues found that the combination of telisotuzumab vedotin and erlotinib showed activity in c-Met protein–expressing advanced non–small cell lung cancer (NSCLC), including those with an EGFR mutation and prior EGFR tyrosine kinase inhibitor treatment.
As stated by the investigators, “Overexpression of c-Met protein and … EGFR mutations can co-occur in … NSCLC, providing strong rationale for dual targeting. Telisotuzumab vedotin, … a first-in-class antibody-drug conjugate targeting c-Met, has shown a tolerable safety profile and antitumor activity as monotherapy.”
Study Details
In the international multicenter study, 42 patients with c-Met–positive disease were enrolled between April 2015 and January 2020; later enrollment was restricted to patients who also had an EGFR-activating mutation and disease progression on a prior EGFR tyrosine kinase inhibitor. Patients received telisotuzumab vedotin at 2.7 mg/kg once every 21 days plus erlotinib at 150 mg once daily.
A total of 36 patents were evaluable for efficacy, including 26 with an EGFR mutation. The efficacy-evaluable population consisted of those patients with a confirmed histology (H)-score ≥ 150 who had at least one postbaseline scan; c-Met–positive patients with H-scores ≥ 225 were classified as c-Met high.
Responses
Among all 36 evaluable patients, an objective response was observed in 11 (30.6%, 95% confidence interval [CI] = 16.3%–48.1%) and the disease control rate was 86.1%. Median duration of response was not reached. Median progression-free survival was 5.9 months (95% CI = 2.8 months to not reached).
Among the 28 patients with an EGFR mutation and prior tyrosine kinase inhibitor treatment, objective response was observed in 9 (32.1%, 95% CI = 15.9%–52.4%) and the disease control rate was 85.7%. Median progression-free survival was 5.9 months (95% CI = 2.8 months to not reached).
Among 15 patients with an EGFR mutation with c-Met–high status, the objective response rate was 52.6%. Median progression-free survival was 6.8 months among 15 patients with non-T790M mutations or whose T790M status was unknown, compared with 3.7 months among 13 patients with a T790M mutation.
Toxicity
Among the 42 patients in the safety population, the most common adverse events of any grade were peripheral sensory neuropathy (43%), dermatitis acneiform (38%), diarrhea (33%), and hypoalbuminemia (33%). The most common events considered related to telisotuzumab vedotin were peripheral sensory neuropathy (36%) and peripheral neuropathy (19%).
Grade ≥ 3 adverse events occurred in 64% of patients, most commonly pulmonary embolism (14%); hypokalemia (10%); and diarrhea, malignant neoplasm progression, peripheral sensory neuropathy, and hypophosphatemia (7% each). Treatment-related grade ≥ 3 adverse events occurred in 31%, most commonly hypophosphatemia and peripheral sensory neuropathy (7% each). Death in 1 patient, due to hemoptysis, was considered potentially related to telisotuzumab vedotin.
The investigators concluded: “[Telisotuzumab vedotin] plus erlotinib showed encouraging antitumor activity and acceptable toxicity in EGFR [tyrosine kinase inhibitor] pretreated patients with [EGFR-mutant, c-Met–positive] NSCLC.”
Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, Aurora, is the corresponding author for the Journal of Clinical Oncology article.
Disclosure: The study was funded by AbbVie, Inc. For full disclosures of the study authors, visit ascopubs.org.